Related Experiment Videos
Restless legs syndrome improved by pramipexole: a double-blind randomized trial
J Montplaisir1, A Nicolas, R Denesle
1Centre d'Etude du Sommeil, Hôpital du Sacré-Coeur de Montréal, Québec, Canada.
Neurology
|April 2, 1999
Summary
Pramipexole significantly improved Restless Legs Syndrome (RLS) by reducing leg movements and discomfort. This D3-receptor agonist offers a potent new treatment option for RLS patients.
Area of Science:
- Neurology
- Pharmacology
Background:
- Restless Legs Syndrome (RLS) causes leg discomfort and an urge to move.
- Current treatments like levodopa offer limited symptom control and cause side effects.
Purpose of the Study:
- To evaluate the safety and effectiveness of pramipexole, a D3-receptor agonist, for treating RLS.
Main Methods:
- A double-blind, placebo-controlled crossover study with 10 RLS patients.
- Treatment duration was one month each for placebo and pramipexole.
- Outcomes included home questionnaires and sleep lab recordings measuring periodic leg movements (PLMS and PLMW).
Main Results:
- Pramipexole significantly reduced PLMS and PLMW indexes to normal levels.
- Patients reported decreased leg discomfort at bedtime and during the night.
- Sensory and motor functions improved substantially.
Conclusions:
- Pramipexole demonstrates high potency in treating RLS symptoms.
- The drug normalized both sensory and motor functions in RLS patients.
- Findings support the role of D3 receptors in RLS pathophysiology.